Genmab

	20/5 09:45 af Bulder	Bemærker lige at teclis heller ikke har CRS over grade 2. 30% CR som monoterapi er stærkt. Vi er i 6. linje i gns.
	20/5 09:38 af E L	any thoughts on Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed? (link) not sure if this is the same sub-group as previously presented?
	20/5 08:56 af E L	I didn't realise JNJ are also trying Amivantamab subcutaneous WITHOUT hyaluronidase , so just SC administration of a low concentration (50 mg/mL) formulation of amivantamab alone. Let's hope that works well enough. (link)
	20/5 08:33 af E L	ASCO : Updated results of a phase 1, first-in-human study of talquetamab - (link)
	20/5 08:32 af E L	ASCO : Updated phase 1 results of teclistamab - (link)
	20/5 08:26 af JørgenVarnæs	Bulder 13.56 tusind tak for info
	20/5 08:21 af Solsen	Bemærkningen “mostly manageable” er da interessant, som også bulder fremhæver 23:35
	20/5 08:09 af Helge Larsen/PI-redaktør	Er svagheden i biotekaktier forbigående? Bryder Novo Nordisk ud af sit kursinterval? Er inflationsfaren reel – eller er det et buzzword? Samt verden ifølge elonmusk & tsla. Lyt med i afsnit 66 af Investeringspodcasten med PerNordnet ogHelgeLarsen. (link) .
	20/5 07:17 af Helge Larsen/PI-redaktør	Torsdagens danske avisuddrag med Bitcoin, Salling Group og Rockwool: (link)
	20/5 06:53 af Helge Larsen/PI-redaktør	Genmab Announces Abstracts Evaluating Products in Pipeline, Portfolio to be Presented at American Society of Clinical Oncology : (link)
	20/5 06:52 af Helge Larsen/PI-redaktør	God morgen. :-)
	20/5 06:52 af Helge Larsen/PI-redaktør	Genmab vil præsentere data til kommende konferencer - GENT (link)
	19/5 23:50 af Bulder	Responser synes jeg er svært at udlede, men epco nævner 55% CR og glofi nævner 57,1% CMR i dlbcl. Altså næsten det samme. Med alle forbehold.
	19/5 23:46 af peter12	Media release (link)
	19/5 23:35 af Bulder	Well, glofi har 3 pts ud af 52 med CRS grade 3. Epco har ingen over grade 2. Glofi: CRS was mostly(!) manageable.
	19/5 17:21 af E L	a much better way to spend your time lol, enjoy!
	19/5 17:19 af Helge Larsen/PI-redaktør	E L I play football tonight with the young people in the club. Must therefore, as usual, go to bed early and get up late tomorrow. :-D
	19/5 17:16 af Darvin	Rigth EL 17.10 65% increase compared to april 2020 and 46,5% increase compared to først 4 months 2020. Excellent
	19/5 17:12 af E L	good luck Helge, looking forward to the summaries tomorrow morning ;-)
	19/5 17:11 af GeorgeBest	Thanks E L & Bulder
	19/5 17:11 af Bulder	asco abstracts are released at 23.00 tonight
	19/5 17:10 af E L	didn't check but could be an all time high % change over last year...
	19/5 17:09 af E L	yes, last year apr and may was slow, wasn't it, great % rise over last year this month
	19/5 17:06 af Darvin	Ikke - 6 men +6

	19/5 17:06 af E L	and by the way that eha data was very good, and will get more attention at ASCO
	19/5 17:05 af Darvin	Tak Helge. Mindre rettelse - 6% stigning ift marts, da der var en arbejdsdag mindre. Fortsat rigtig fint. Væsentligt bedre 4 mdr i 21 end de første 4 i 20
	19/5 17:04 af E L	i know, but the EHA and ASCO abstract had to be sent in around the same time, so the data can not be (much) different i think. They may elaborate with a bit of an update again in June, during the presentation though?
	19/5 17:00 af GeorgeBest	Okay E L. I just had this comment in mind from Jan, and it was related to ASCO: „ Let us start with our own product candidates. There will be an important presentation on epco data from the initial Phase I/II study. This presentation will highlight the promise and success of our DuoBody platform..“
	19/5 16:59 af E L	thanks Helge; solid number; next month over >300
	19/5 16:57 af E L	But I think we have see all the epco data we will get in the EHA abstract this week tbh
	19/5 16:57 af Helge Larsen/PI-redaktør	Sorry. I've been busy all day with podcasts and video production. Darzalex April was $ 298M. Increase of just over 10% as there were 2 working days less compared to March. :-)
	19/5 16:57 af E L	I am sure Helge will categorise them appropriately ;-)
	19/5 16:55 af GeorgeBest	Dara abstracts are boring ;-) I am more interested in the next winner...
	19/5 16:50 af E L	:-D Helge is absent today because he needs to sleep whole day; he will need the whole night to prepare summaries for us for tomorrow morning ;-) 60 Dara abstracts lol
	19/5 16:46 af GeorgeBest	E L, when do you have the ASCO abstracts for us? ;-)
	19/5 15:13 af E L	@_Hubrecht & @Genmab received the Galien Excellence COVID-19 Award for the STRIP-1 SARS-CoV-2 testing robot (link)
	19/5 15:01 af Bulder	Stadig ingen SH-tal?
	19/5 14:55 af E L	;-)
	19/5 14:52 af Bulder	Yes, Blenrep, once a threat, now a partner. They all want to make friends with dara.
	19/5 14:42 af E L	it seems they forgot epco at EHA ;)
	19/5 14:42 af E L	AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO (link)
	19/5 14:28 af E L	lol, new trial: Blenrep in combi with Dara - (link)
	19/5 14:22 af E L	Gilead’s Magrolimab is an Investigational Anti-CD47 Monoclonal Antibody- in new trial with a.o. Dara here for MM (link) (just after Sukkeralf asked Jan about the Blink cooperation...)
	19/5 13:58 af Bulder	Det har i øvrigt vist sig at give færre bivirkninger end IV, selv om denne indgives over mange timer.
	19/5 13:56 af Bulder	JV 11.35: Kesimpta gives med autoinjektor med 20 mg. Dara Faspro er 1800 mg. Det gør en forskel, som nødvendiggør hyaluronidase, som får dara til at ligge i et reservoir under huden, så det optages langsomt.
	19/5 12:40 af Bulder	Ingen tvivl om at det afgørende spm ved hexa38 er tåleligheden. Når man i sin tid var skeptiske ved dara, skyldes det at cd38 findes overalt i kroppen. Så med et endnu mere potent stof, kan det måske volde problemer.
	19/5 12:31 af Bulder	Nogen SH-tal?
	19/5 11:44 af JørgenVarnæs	Nice! Thx EL
	19/5 11:43 af E L	my queston was exactly on that 'do you anticipate that Hexabody-CD38 could potentially be given subcutaneous (without the need for eg. Halozyme)?'
	19/5 11:42 af E L	that is why i hoped for the same with hexacd38, and Jan's answer was in the same direction: 'At this moment we are testing different doses of HexaBody Cd38 in mm patients. If the efficacy follows the very promising preclinical profile it may indeed be possible to use 3 / 6 Q&A GENMAB 17TH OF MAY 2021 WITH JAN VAN DE WINKEL far lower doses than with daratumumab. If that follows from the clinical testing, we may be able to dose subcutaneously without hyaluronidase in deed.'